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This document provides guidance on quality assurance (QA) practices for sites 
using or planning to use rapid test kits to detect antibodies to the human 
immunodeficiency virus (HIV) waived under the Clinical Laboratory 




rapid HIV tests 
Waived rapid HIV tests are test devices or kits cleared by the U.S. Food and Drug 
Administration (FDA) that are determined to meet the criteria for waiver under 
CLIA.1  They are simple, single-use, disposable devices, using minimal reagents, 
that can provide results in less than 60 minutes and are designed for use with 
unprocessed specimens (whole blood or oral fluid specimens).  Rapid HIV tests, 
when used with specimens that require processing, such as plasma or serum, are 
not waived under CLIA. 
 
 
How rapid HIV  
tests are used 
Rapid HIV tests are used as screening tests to detect antibodies to HIV as part of 
multi-test algorithms to aid in the diagnosis of infection with HIV.  Positive 
(reactive) rapid HIV test results are preliminary and must be followed up with an 
approved confirmatory test. 
 
 
Importance of a  
QA program 
 
Although waived rapid HIV antibody tests are simple to use and can provide 
reliable results when the manufacturer’s directions are followed, mistakes can 
occur at any point in the testing process.  To reduce mistakes and to ensure that 
the FDA restrictions for sale of these tests are followed (see Appendix A for 
information on the FDA sales restrictions), the testing site must have a QA 
program in place before offering waived rapid HIV antibody testing.  The 
guidelines in this document outline the basic elements of a QA program.  
 
 
How to use these 
guidelines 
These guidelines are intended to assist a range of providers in developing 
policies, processes and procedures to ensure high quality HIV testing services.  
The contents include a description of steps that should be taken to identify and 
prevent errors in the testing process.   Because rapid HIV tests are used in many 
different settings, each site needs to decide how best to fit the various QA 
elements into its own operation.  For example, the QA program in a large clinic 
or hospital where on-site laboratory support is available may be quite different 
from an outreach setting with fewer personnel and resources. 
 
 
How this document 
is  organized 
This document and its appendices provide basic information that personnel who 
offer waived rapid HIV testing should know.  It includes information on: 
 
 Basic elements of a QA program 
 An overview of government rules that apply to using waived rapid  
HIV tests. 
 Examples of forms and checklists that can be used to record and monitor 
QA processes and procedures.   
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Basic Elements of a Quality Assurance Program 
 
 
What is quality 
assurance? 
 
Quality assurance (QA) refers to planned, step-by-step activities that let one know 
that testing is being carried out correctly, results are accurate, and mistakes are 
found and corrected to avoid adverse outcomes.  Quality assurance is an ongoing 
set of activities that help to ensure that the test results provided are as accurate 
and reliable as possible for all persons being tested. These activities should be in 
place during the entire testing process, from the time a person agrees to be tested 
until after the test results are provided.  
 
 












As described above, QA is an overall program of activities throughout the entire 
testing process.  Quality control (QC) is one part of the QA program.  Here are 
definitions for both terms2: 
 
Term Definition and activities performed 
Quality assurance Planned and organized activities to help ensure that 
certain requirements for quality will be met. 
Quality control Operational techniques or tasks that are in place to find 
and correct problems that might occur.  
          
Basic elements of a 
QA program for 
rapid HIV testing 
Even though waived tests are simple to use, things can go wrong.  To help find 
and prevent problems, the basic elements of a QA program should be in place 
before offering testing.  More detail on these six elements is provided in this 
document. These basic elements are the building blocks of a QA program and are 
listed below.   
 
1. Organization of the QA program 
2. Testing personnel 
3. Process control 
a. Before testing 
b. During testing 
c. After testing 
4. External assessment  
5. Documents and records 
6. QA evaluation and troubleshooting  
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1. Organization of the QA Program 
 
 
Establishing a QA 
program 
 
A QA program, no matter how simple, requires resources.3 Someone must 
oversee the program and ensure the necessary personnel and supplies are 
available.  Each organization must: 
 Identify the person(s) responsible for managing the QA program (this 
could be a senior staff member, outside consultant or a network of 
individuals who oversee different aspects of the QA program). 
 Verify the testing process. 
 Write site-specific procedures (step-by-step instructions) and make them 
available to all personnel involved in testing. 
 Ensure personnel know how to perform each of the procedures. 
 Create mechanisms for communication so that personnel are informed 
about problems when they are identified.   
 Have a CLIA Certificate of Waiver if performing only waived rapid HIV 
antibody or other waived tests, or be included under an organization with 
a CLIA exception for limited public health or mobile testing. (See 
Appendix A for more information on regulatory requirements.) 
 Develop and implement mechanisms to ensure the site meets all 
applicable Federal, State, and other regulatory requirements, including 






Before offering the test to clients or patients, each site should make sure (verify) 
that the testing process works as planned.  Verifying the process includes: 
ensuring that personnel have been trained and are able (competent) to perform 
their assigned tasks, the test kits work as expected (e.g., give accurate results for a 
referenced panel of nonreactive, weakly reactive, and reactive specimens), and 
that logistics are in place for providing confirmatory testing of preliminary 
positive test results and handling biohazardous waste. 
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Testing personnel must follow instructions provided by the manufacturer.  It is 
strongly recommended that step-by-step, written instructions be made available to 
all personnel performing testing.  The test kit package insert provides text that can 
be used as a procedure for steps in the testing process listed below: 
 
Procedure Describes how to... 
Pretest information provide required pretest information to test subject. 
Materials and 
storage 
maintain sufficient supplies of unexpired test and 
control kits and adhere to the manufacturer’s 
temperature ranges for storage and testing areas. 
Test performance collect specimens, perform the test, interpret and report 
test results, resolve problems (troubleshoot) before 
reporting results. 
Quality control check performance of new test kit lots and shipments, 
frequency of routine QC testing, and actions to take if 








Site-specific procedures describing other operations should be written and 
available to help ensure personnel know how to perform additional QA tasks: 
 
Procedure Describes how to... 
Personnel training 
and competency 
train and assess competency of new employees; 
periodic competency assessment of all testing 
personnel. 
Safety use gloves and other personal protective equipment 
(PPE); safely dispose of biohazard waste, including used 
lancets or other sharps used for blood collection. 




refer specimens or test subjects for confirmatory testing; 
manage test results. 
Documentation keep records and timelines for review, retain and 
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Having qualified, trained personnel who perform and supervise rapid HIV testing 
and the various activities in the QA program is one of the most important factors 
for ensuring accurate and reliable results.  Key aspects of this element include: 
 Qualifications 
 Training 






There are no Federal requirements for who can perform waived tests; however, 
some States have specific requirements for testing personnel.  Beyond any 
regulatory requirements, it is recommended that certain qualities be considered 
when selecting personnel to perform rapid HIV antibody testing.  The following 
list of desirable qualities is based on practical considerations and expert opinion: 
 Sincerity and commitment – A dedication to performing testing 
accurately, according to defined procedures. 
 Literacy – The ability to read instructions and record results is critical. 
 Organizational skills – The level of skill necessary will depend on the 
number and complexity of tasks an individual performs in the testing 
process.  If test volume is high and the individual performing testing is 
doing several tests or managing several other tasks simultaneously, 
organizational skills can be critical. 
 Decision-making skills – Testing personnel should be able to interpret 
results and be able to recognize and handle problems that might arise. 
 Communication skills – If the person performing the test also is the one 
who shares results or other information with the person being tested, 
being able to communicate clearly is important. 
          
Components of 
training 
Training is crucial to ensuring quality testing.4 Assurance that personnel who 
perform testing receive training information is required to purchase rapid HIV 
test kits (see Appendix A for the FDA sales restrictions).  Personnel should be 
fully trained on how to perform their assigned tasks and responsibilities.  Training 
should be documented for each individual; using training checklists is one way to 
handle this documentation (see Appendix B for an example checklist).  The key 
components to include in a training program are: 
 The importance of QA and the elements of the site’s QA program  
 How testing is integrated into the overall program  
 How to perform the test, including procedures performed before, during, 
and after testing. 
 The use and importance of blood and body fluid precautions and  
biohazard safety. (See Biohazard Safety/Universal or Standard 
Precautions.) 
        Continued on next page 
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2. Testing Personnel, continued 




A training method should optimally include the following activities: 
 Read the instructions for performing the test. 
 Watch someone perform the test or view a video of someone performing 
the test. 
 Practice performing the test with positive and negative control materials. 
 Practice performing the venipuncture, finger-stick and/or oral fluid 
collection procedure. 






Before a trainee is permitted to perform testing alone for the first time, his or her 
ability to conduct the test should be demonstrated and documented.  This 
assessment should also be carried out at periodic intervals after training, such as 
every six months or other interval as determined by the testing site.  Competency 
assessment can be carried out in many ways, but regardless of the method, every 
task for which an individual is responsible should be evaluated.  A supervisor or 
trainer should perform the assessment, using a combination of methods to 





tasks done before 
testing 
To assess task performance before testing, personnel should be observed as they: 
 Check and record the temperatures of the testing and storage areas. 
 Set up the testing area, label the test device and prepare control and test 
results log sheets. 
 Run the external controls and record results. 
 
 
        Continued next page 
QA Guidelines for Waived Rapid HIV Antibody Testing 
   
 
9  





tasks done during 
testing 
 
To assess personnel’s ability to perform the test and interpret results: 
 Observe personnel performing specimen collection and handling 
according to the manufacturer’s instructions. 
 Observe how the test is performed on a client/patient.  If such observation 
will interfere with the actual client-provider interactions, observe test 
performance on a volunteer. 
 Evaluate the use of Universal or Standard Precautions and procedures for 
biohazard and sharps (e.g., lancets, needles) waste disposal. 
   Review results obtained from testing a panel of referenced specimens that 
show a range of results, such as five specimens that include nonreactive, 
weakly reactive, and reactive results.  Control materials supplied by the 
manufacturer may be used as a source of specimens in the panel.  In 
addition, specimens may be obtained from laboratories performing 
confirmatory testing or from other commercial sources.  
 
   Appraise the individual’s ability to interpret results. This might include 
using previously used test devices or pictures of devices that show 
nonreactive, weakly reactive, reactive, and invalid results. 
 




tasks done after 
testing 
 
To assess task performance after testing: 
 Review test records and quality control results for proper documentation. 
 Observe oral reporting of results to a test subject (if trainee’s 
responsibility). 
 If confirmatory test specimens are collected on-site, observe the 
collection and handling of venous blood and/or oral fluid specimens for 
referral.  If the frequency of reactive rapid test results is low, the trainee 
should be observed collecting blood and/or oral fluid from a volunteer 
staff member and demonstrate how it is processed for confirmatory 
testing. 
 Verify that confidentiality is maintained. 
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3. Process Control 
 
 
What is process 
control? 
 
Process control refers to the activities and techniques that are carried out to 
ensure that the testing procedures are performed correctly, the environment is 




Steps in the testing 
process 
Steps in the testing process follow the path of workflow beginning with tasks 
before testing, followed by those conducted during and after testing.  This path of 
workflow and the associated steps are shown in the table below.  Detailed 
descriptions about each of the steps listed in this table are provided in the 










Before testing During testing After testing 
 Check storage and room 
temperatures daily 
 Check inventory and test kit lots, 
as needed 
 Receive request for testing 
 Provide HIV/AIDS test 
information to the test subject 
 Set up test area, label test device 
 Perform external QC according to 
the manufacture’s and the site’s 
instructions 
 
 Follow biohazard 
safety precautions 
 Collect the blood or 
oral fluid specimen 
 Perform the test 
 Interpret the results 
 Document results 
 Report results to test subject 
 Collect, process, and 
transport confirmatory test 
specimens or refer 
clients/patients for follow-
up 
 Clean up and dispose of 
biohazardous waste 
 Manage confirmatory test 
results 
 Participate in periodic 





Steps in the testing process 
(Path of Workflow) 
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As shown in the table above, there are a number of steps that must be followed 
before testing a specimen.  These activities are in place to ensure that the 
conditions at which the test kits and controls are stored and tests are performed 






test and control 
kits storage 
 
Test kits and controls must be stored within the temperature ranges specified by 
the manufacturer. These ranges vary with different test kits.  Place thermometers 
in refrigerators and monitor areas where kits are stored.  Check and record 
temperatures of the storage area on a log sheet each day testing is performed. An 
example temperature log is provided in Appendix C.   
NOTE:  “Min-Max” thermometers maintain a record of the highest and lowest 
temperature recorded during the observation period and can be very helpful to 







The temperature in the area where the test will be performed must be within the 
range specified by the manufacturer.  For testing carried out in the field (not on-
site), monitor the temperature of the test and control kits in their portable storage 
containers and check the temperature where testing will be performed if it appears 





out of range 
 
If the temperature falls outside of the specified range, take action as needed to 
adjust the temperature. If there are doubts about the testing area temperature or 
whether test kits have stayed within the appropriate temperature range, run 
external controls as described in the QC section below to ensure test devices are 





Procedures should be in place to ensure adequate supplies of unexpired test kits, 
controls, and other materials and should include:   
 Rotating inventory to ensure the oldest kits are used first. 
 
 Adhering to shelf life limitations defined by the manufacturer.   
o Test or control kits should never be used beyond their expiration 
dates.  
o Discard any test kits that are past their expiration date.  
o Once control vials are opened, their shelf life is reduced. It is 
helpful to record on the control vial the date it is opened and the 
date after which the opened control expires. 
NOTE: It is useful to document on a log sheet when test and control kits are 
received, their lot numbers and their expiration dates. (See Appendix D for an 
example log sheet of control results.) 
 
          
         Continued next page 
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3a. Before Testing, continued 
         
 
Setting up the 
testing area  
 
The testing area should be prepared according to the specific site procedure, 
which should include directions for:  
 
 Setting up the workspace and organizing supplies, 
  
 Ensuring lighting is adequate to interpret rapid HIV test results.   
As a rule of thumb, lighting is sufficient if standard newsprint held next 
to the test device can be read without difficulty. (See page 12 for 
additional information on interpreting results.),  
 
 Preparing the test kit components and controls, 
 
 Completing report forms.    
 
NOTE: If test kits are refrigerated, test devices, other kit components, and 
controls should be brought to room temperature before opening and performing 





labeling the test 
device 
 
It is critical to correctly identify each person to be tested and to ensure that proper 
identification of the specimen is maintained throughout the testing process.   
Labeling is especially important when more than one test is being performed at 
the same time. Using preprinted labels improves the efficiency of performing this 
task. Label components of the test (e.g., vials of developer solution, test device, 
and test result logs) with the name or identifying number of the person being 
tested before collecting the specimen.  
                   
 
Providing 
information to  
test  subjects 
 
Manufacturers of rapid HIV tests provide a subject information pamphlet that 
must be given to each person prior to performing the HIV rapid test, in 
accordance with FDA sales restrictions.  Each site may provide additional 
information.  For further details, see the CDC website 
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3a.  Before Testing, continued 




Waived rapid HIV tests include two types of QC.  These are described in the table 
below. 
 
Type of quality control Description of activity 
Internal controls Controls built into each testing device 
can verify the specimen was adequate 
and the solution flowed through the 
device as intended.  Functions of 
internal controls vary by device. 
External controls Known reactive and nonreactive 
liquid samples (controls) are either 
provided in each test kit or purchased 
separately from the manufacturer.  
External controls are surrogate 
samples used to evaluate the integrity 
of the test system and whether the 







To verify that test devices accurately detect antibodies to HIV, external positive 
and negative controls must be tested from time to time.  The test kit manufacturer 
provides external controls containing HIV antibody-negative (nonreactive) and 
positive (reactive) human plasma compatible with its test system.  Before using 
external controls from a different source, contact the test manufacturer to verify 
they are compatible with the specific test system being used and evaluate them in 
the testing site.  Controls may be ordered separately from the test kit depending 
on the manufacturer. 








Follow the manufacturer’s instructions for when to run negative and positive 
controls.  These instructions recommend running external controls under the 
following circumstances: 
 By each new operator prior to performing testing on clients/patients for 
the first time,  
 When opening a new test kit lot (a test kit lot is defined as boxes of test 
devices that have the same lot number label on the outside of the box), 
 Whenever a new shipment of test kits is received (even if it is the same 
kit lot number in current use), 
 If the temperature of the testing area falls outside of the range specified 
by the manufacturer, and 
 At periodic intervals as determined by the testing facility. 
 
         
         Continued next page 
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3a.  Before Testing, continued 






How often controls are run will depend on the number of tests performed by the 
site, how often new test kit shipments or lot numbers are received, changes in 
storage and testing area temperatures, and turnover of testing personnel. Sites 
testing large numbers of persons, and especially those offering anonymous 
testing, should plan to run controls more often than facilities conducting fewer 
tests.  Each site needs to decide how often to run controls based on its own 
situation and testing practices. Control results should be documented. (See 






When external controls give incorrect results, none of the tests that were run since 
the last time control results were correct can be considered valid until 
troubleshooting is done to determine the source of the problem. If test kits are 
determined to be faulty, everyone who was tested since the last time control 
results were correct may need to be called back and retested (unless a 
confirmatory test was ordered).  Results of client retesting should be documented 







If external controls do not give the correct result, steps should be taken to 
determine the source of error by following the external control kit troubleshooting 
instructions. Troubleshooting steps help determine if the source of error is the test 
kit, the external controls, or operator technique. When necessary, contact the 
manufacturer for assistance and/or to report defective test system components. 









This phase of the testing process involves running the test and interpreting the 
results.  Activities during testing include collecting the specimen, performing the 
test, interpreting the internal control and client/patient test results, and following 






Follow the written procedure for whole blood or oral fluid specimen collection, 
labeling, and handling.  Further information on collecting blood by skin puncture 
can be found in Procedures and Devices for the collection of Diagnostic 
Capillary Blood Specimens; Approved Standard – Fifth Edition.5 
 
 
        Continued next page  
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3b. During Testing, continued  
 
 




Follow the manufacturer’s step-by-step instructions for performing the test and 
interpreting the results.  Interpreting rapid HIV tests requires good eyesight and 
adequate lighting. The test should be read from a comfortable distance without 
manipulating the test device. If supplemental lighting, such as a flashlight, is 
necessary, care should be taken to avoid shadows or reflections that might lead to 
an incorrect interpretation of the test. (A flashlight should never be used to shine 
light through the test device to accentuate the test result.) Test results can be one 
of the following: 
 
 Nonreactive (report as negative) 
 
 Reactive (report as preliminary positive)  
 





Each rapid test device includes a built-in (internal) control.  Internal controls in 
test devices vary among test manufacturers, therefore, it is important to read and 
understand the manufacturer’s explanation of the location and functioning of 






Internal control results are evaluated with every test.  If the internal control does 
not produce the expected result, the test result for the client/patient is invalid, 
cannot be reported, and the test must be repeated.  If a second invalid result 
occurs, external controls should be evaluated as described below before repeating 









If repeatedly invalid test results or an unexpectedly high number of reactive 
results are obtained during testing sessions, external controls should be run to 
help find out if problems are due to faulty test kits, improper testing procedures, 
or something to do with the patient specimen. It is important to run the positive 
and negative controls whenever two consecutive invalid test results are obtained 
on a person being tested.  If the external control results are valid, the problem 
may be due to interfering substances in the client’s/patient’s specimen. 
 
 
        Continued next page  
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All specimens and materials contacting specimens must be handled as if they are 
capable of transmitting an infectious organism.  As described in Appendix A, 
each site must ensure that the Occupational Safety and Health Administration 
(OSHA) bloodborne pathogens standards are met.  Persons doing the testing must 
know how to safely handle potentially infectious specimens.  Also, according to 
Universal Precautions, all human blood and certain body fluids should be treated 
as if know to be infectious for HIV, hepatitis B virus, hepatitis C virus, and other 
bloodborne pathogens.  Sites must have available, and follow procedures for, 
biohazard safety to include instructions for the use of gloves, hand washing, 
sharps and biohazardous waste disposal, spill containment and disinfection.  A 
different pair of gloves should be worn for collecting a specimen from each 
person being tested.  Used gloves should be handled as biohazardous waste.  For 
further details on these precautions see the manufacturer’s package insert, OSHA 
regulations and guidelines on Universal and Standard Precautions.2,6,7,8  
 
        





Quality assurance extends to those activities completed following the 
performance of the test. Each site should have established procedures for: 
 
 Reporting and recording results, 
 Referring specimens (or test subjects, if specimens are not collected  
on-site) for confirmatory testing, 
 Managing confirmatory test results, and 





Reporting procedures should describe how results are provided to the person 
being tested (verbal and/or written results) and how results are documented in the 
person’s chart and in the test result logs.  (See Appendix E for an example of a 
test result log.)  






Whenever a rapid HIV test result is reactive (preliminary positive), follow-up 
testing must be performed to confirm that the person being tested is infected with 
HIV.  Therefore, each site must have established procedures for referral of either 
test specimens or persons being tested for confirmatory testing when rapid test 
results are reactive. Collecting confirmatory specimens on-site may improve 
follow-up, since some clients/patients may not go elsewhere for the testing or to 
obtain results. However, if the site is not able to collect confirmatory test 
specimens, a procedure must be in place for referring clients/patients to another 
site to obtain this testing.  
NOTE:  If the client/patient refuses confirmatory testing, this should be 
documented in the test results log.  
 
        Continued next page  
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If specimens are collected on-site, the site must establish procedures describing:  
 
 How to collect, label, process, store, and document specimen transfer.  
Note: It should be indicated on the referral laboratory test requisition that 
the specimen is from an individual who has had a reactive rapid HIV test 
result. (See Appendix F for an example specimen transfer log.) 
  
 Transportation of the confirmatory test specimens to the site(s) where 
they will be tested.  
 
 How confirmatory results are obtained to give to the client/patient. 
 
 How to report confirmed positive HIV results to your state health 






for a reactive rapid 
HIV test   
 
For confirmatory testing of reactive (preliminary positive) rapid test results, 
recommended testing algorithms are as follows:  
 
 All reactive (preliminary positive) rapid test results must be followed up 
with an approved supplemental test, such as a Western blot, an 
immunofluorescent assay (IFA) or an RNA 9,10 test, for confirmation. 
 
 Confirmatory testing can be done on blood (plasma, serum, or dried 
blood spots) or oral fluid specimens, though blood specimens have higher 
accuracy than oral fluid specimens. Urine should not be used for 
confirmatory testing because of its lower sensitivity.  
 
Performing an enzyme immunoassay (EIA) screening test prior to a confirmatory 
test is optional. Even if the EIA is nonreactive, the specimen must proceed to 
confirmatory testing with a Western blot, IFA, or RNA.  
 
Follow-up testing 




Most confirmatory test results will be positive; however, some may be negative.  
A negative confirmatory test result indicates one of three possibilities: specimen 
mix-up, early seroconversion (too early for antibody detection by Western blot or 
IFA), or false positive rapid test result. If the initial confirmatory test is negative, 
it is recommended that: 
 
 For blood specimens, a repeat confirmatory test with a new blood 
specimen should be done to rule out specimen mix-up or early infection. 
 
 For oral fluid specimens, a repeat confirmatory test with a blood 
specimen should be done because the Western Blot test is less accurate 
with oral fluid than it is with blood.  
 
        Continued next page 
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Occasionally, confirmatory test results are indeterminate.  If the Western blot or 
IFA is indeterminate, it is recommended that: 
 If the initial confirmatory test was conducted on blood, the person should 
be advised to return for repeat confirmatory testing in one month or a test 
for HIV RNA may be performed.  
 If the initial confirmatory test was conducted on oral fluid, a repeat 
confirmatory test (Western blot, IFA, or RNA) should be conducted using 
a blood specimen. 
See CDC’s Revised Guidelines for HIV Counseling, Testing and Referral found 
at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5019a1.htm  
 









Procedures should describe how to handle result discrepancies when the rapid test 
result was reactive and the confirmatory test was negative or indeterminate.  If the 
laboratory providing confirmatory testing performed an EIA test only and 
reported a nonreactive or negative result, the testing site should contact the 
confirmatory testing laboratory and request a Western blot, IFA, or RNA test.  If 
the original specimen is not available, a new specimen will need to be collected to 
be used for confirmatory testing. 
 
 
QA Guidelines for Waived Rapid HIV Antibody Testing 
   
 
1 9  
4. External Assessment  
 
 
Overview   
 
External assessment, an evaluation of the testing process by an impartial outside 
source, is a way to evaluate how well testing is being performed and whether it is 
being performed reliably.  It can help to identify existing or potential problems.  
Moreover, information gathered can provide an educational tool to improve 
performance.  Although not required by Federal (CLIA) regulations for waived 







Every reactive test is externally assessed by a second, confirmatory test.  
However, if there is a low prevalence of HIV infection in the population being 
tested, these assessments may be rare and will not provide an external check for 
the majority of the results, i.e., those that are nonreactive.  Other ways to assess 
performance may be needed. Some external assessment mechanisms include: 
 Comparing the reactive results with the confirmatory test results. 
 Arranging for someone outside the organization to observe testing. 
 Participating in a proficiency testing (PT) or external performance 
evaluation program. (For more information on these programs, see 
Appendix G.) 
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One of the hallmarks of an adequate QA program is comprehensive 
documentation.  Sites using waived rapid HIV tests should have policies and 
procedures describing what QA records are required and how and when they are 
reviewed, stored, and destroyed.  Having a supervisor review records periodically 
is recommended.  State regulations or other governmental or accrediting agencies 
may require facilities to have specific record retention policies.  QA records 
include the following: 
 Training documentation (Appendix B) 
 Temperature logs (Appendix C) 
 External control result logs (Appendix D) 
 Test result logs (Appendix E) 





Temperature logs should include a daily record of the refrigerator and/or room 
temperature where test kits and external controls are stored and the temperature of 
the testing area.  Thermometers should be placed in each location.  Laboratory 
grade thermometers, which can be purchased from medical or laboratory supply 
houses, are recommended and their accuracy checked periodically (e.g., every six 
months) by comparison with another thermometer. 





External control records should include the date and time of control testing, lot 
number and expiration date of the test kit, lot number and expiration date of the 
controls, control results, and corrective action taken if control results are 
unacceptable.  Control records should be kept in the order in which they were 
completed so they can be easily compared with the test records.  This will help 




Test result logs 
 
Test result records should include the date and time of testing, an identifier for the 
person being tested, a test kit lot number and expiration date, test result, action 
taken if the result was invalid, identification of the person who performed the test, 
whether confirmatory testing was requested, including the type of specimen sent 
for confirmation (e.g., oral fluid, blood), and the confirmatory test results when 
they are available.  If more than one person is conducting testing, there should be 
a mechanism to chronologically link the test record log sheets to detect problems, 
such as invalid results occurring repeatedly with the same test kit lot number. 
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Each site should have protocols to identify key QA measures that are routinely 
monitored and evaluated and have corresponding troubleshooting procedures to 
resolve problems that may occur.  Significant problems, especially those 
concerning the accuracy of the rapid HIV test in use should be immediately 
reported to the QA manager or appropriate supervisory personnel. The local or 




QA monitoring  
 
QA managers should routinely monitor and evaluate QA measures. Some 
suggested measures include the following:  
 Number of tests or external control materials that expired before use or 
occurrences of expired tests used for diagnostic or QC purposes  
 Number of days tests or QC materials were stored or used outside of 
temperature specifications  
 Frequency of external QC testing compared with test site procedure  
 Frequency of invalid or incorrect results for external control testing or 
patient/client testing 
 Proportion of negative and preliminary positive patient/client results  
 Proportion of reactive rapid test results confirmed positive of all reactive 





Troubleshooting procedures should be available to all testing personnel and 
include the following: 
 When to discontinue testing, for example, when the external control 
results are unacceptable as described in the package insert 
 How to take corrective action, or an action taken in response to a 
problem, such as contacting the manufacturer when the external control 
results are unacceptable and following the advice provided 
 How to document problems and actions taken, such as a logbook where 
problems and corrective actions can be recorded 
 How to verify the corrective actions taken addressed the problem 
NOTE: In accordance with Federal regulations, manufacturers of diagnostic 











QA Guidelines for Waived Rapid HIV Antibody Testing 
   
 
2 2  
6. QA Monitoring and Troubleshooting, continued 
          
Expired tests or 
QC materials  
When tests or external controls expire before they can be used for testing, 
QA managers should consider evaluating the following: 
 Inventory management, ordering, and storage procedures, to 
ensure materials have a reasonable shelf life 
 The use of test and control materials  
 If needed, adjust ordering procedures, revise QA protocols, or 
retrain staff. 
 
Tests or QC 
materials stored or 




When tests or external controls are used or stored outside of the manufacturer’s 
temperature specifications, QA managers should consider the following actions: 
 Determine the cause for out-of-range temperature(s) and ensure corrective 
measures have been taken. 
 Confirm whether tests were used in out-of-range temperatures, if 
procedures were followed, and if testing personnel were aware of 
temperature conditions. 
 Determine whether external QC tests were performed to verify the test 
could be performed and correctly interpreted. 








Because of the costs associated with rapid tests, QA managers should monitor the 
ratio of tests used for diagnostic purposes to tests used for external QC purposes.  
If the ratio is less than 20 patient/client tests for each set (positive and negative) 
of external controls tested, then the number of tests used for external QC may be 
excessive.  (Twenty tests is the smallest number of CLIA-waived rapid tests 
manufacturers provide per kit.11-13 )  If external QC testing is excessive because of 
the interval defined by the specific test site procedure (e.g., daily), consider 
adjusting the frequency of QC testing (e.g., from daily to weekly, bi-weekly, or 
monthly) to a more appropriate interval.  
 
 
        Continued next page
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6. QA Monitoring and Troubleshooting, continued 
 
Incorrect or  
invalid QC test 
results 
QA managers should consider the following procedures when incorrect or 
invalid QC test results are observed: 
 Evaluate procedures for testing external controls and review 
records of control results. 
 Perform troubleshooting procedures in accordance with the 
manufacturer’s control kit instructions to determine the source of 
the incorrect or invalid result.   
 If test devices used with valid external control materials provide 
invalid or incorrect results, discontinue testing and contact the 
manufacturer.   
 Resume testing only after tests on external control materials 
provide correct results and document corrective actions.  
 If needed, modify the QA protocol and/or retrain staff on 



















QA managers should consider the following actions when excessive invalid 
client test results are observed:      
 If possible, observe specimen collection, testing, and result 
interpretation to confirm test procedures are performed correctly.   
 Confirm the test device(s) used had not expired.  
 Review documentation of testing to ensure procedures are being 
followed. 
 Determine whether external controls were tested after the second 
invalid test result and if troubleshooting procedures were followed.  
If not, perform external QC testing using test devices from the 
same kit or lot to determine proper functioning of the test device.   
 Perform troubleshooting procedures according to the 
manufacturer’s instructions. 
 If test results using valid external control materials provide invalid 
results, testing should be discontinued.  
 If the test kit/lot is determined to be faulty, notify the 
manufacturer.  
 Resume testing only after tests on external controls provide correct 
results and document corrective actions. 
 If needed, retrain staff on appropriate testing procedures.   




        Continued next page
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QA managers should periodically compare the total number of reactive rapid test 
results with the number of confirmed positive results. If the resulting ratio of 
false-positive rapid test results suggests the test is not performing according to the 
manufacturer’s specifications (refer to the product insert for population 
prevalence and performance data), QA managers should consider the following 
actions:   
 Evaluate the expiration dates of test kits and temperatures of the storage 
and testing areas for test kit lots that produced, and did not produce, false 
positive test results.   
 Review records of external control testing for test devices of the same lot 
and subjected to the same temperature conditions.  
 Perform additional troubleshooting procedures in accordance with the 
manufacturer’s instructions.  
 Evaluate facility testing procedures and, if appropriate, modify the QA 
protocol and/or retrain staff on appropriate testing procedures.   
 If necessary, inform the manufacturer and appropriate local or state 
health department HIV test managers. If appropriate, consider 
discontinuation of testing or changing to another waived test vendor.   
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Acquired immunodeficiency syndrome, caused by the human immunodeficiency virus (HIV),  
can affect the immune and central nervous systems and can result in neurological problems, 
opportunistic infections, or cancers.  
 
CLIA-waived test: 
A test system, assay, or examination that has been cleared by the FDA for home use, or has been 
determined by the FDA to meet the CLIA criteria of being a simple test with an insignificant risk 
for an erroneous result. 
 
Confidentiality:  
Pertains to the disclosure of personal information in a relationship of trust and with the 
expectation that it will not be divulged to others in ways that are inconsistent with the original 
disclosure. Confidentiality must be maintained for persons who are recommended and/or who 
receive HIV counseling, testing, and referral (CTR) services.  
 
Confirmatory test:  
A highly specific test designed to confirm the results of an earlier (screening) test. For HIV 
testing, a Western blot, an immunofluorescence assay (IFA), or an RNA is used as a confirmatory 
test. The person is considered HIV-positive only if the confirmatory test result is positive. 
 
EIA:  
Enzyme immunoassay, sometimes referred to as ELISA, is a commonly used screening test to 
detect antibodies to HIV.  
 
False negative:  
A negative test result for a person who is actually infected.  
 
False positive:  
A positive test result for a person who is actually not infected.  
 
HIV:  
Human immunodeficiency virus, which causes AIDS.  Several types of HIV exist, with HIV-1 
being the most common in the United States.  
 
Indeterminate test result:  
A possible result for a Western blot, which might represent a recent HIV infection or a false-
positive.  
 
Nucleic acid amplification testing:  
A type of testing that identifies viral genes (e.g., specific sequences of nucleic acids) using gene 
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Preliminary positive test:  
For rapid HIV testing, a test result that is reactive by a rapid HIV test and not yet confirmed 
positive by a Western blot, IFA, or approved RNA supplemental test.  
 
Rapid HIV test:  
A test to detect antibodies to HIV that can be collected and processed within a short interval of 
time (e.g., approximately 10 to 60 minutes).  
 
Referral laboratory:  
An external laboratory to which a sample is submitted for a supplementary or confirmatory 
examination procedure and report.   
 
RNA test: 
A test used to detect HIV-1 in plasma using nucleic acid amplification. The test may be 
used as a confirmatory test for a reactive rapid HIV test result to aid in the diagnosis of 
infection with the virus.   
 
Screening test:  




Initial development of detectable antibodies specific to a particular antigen; the change of a 
serologic test result from negative to positive as a result of antibodies induced by the introduction 
of antigens or microorganisms into the host.  
 
Western blot:  
A laboratory test that detects specific antibodies to components of a virus. Chiefly used to 
confirm HIV antibodies in specimens found to be reactive using a screening test.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
